Stockreport

REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD [Yahoo! Finance]

REGENXBIO Inc.  (RGNX) 
Last regenxbio inc. earnings: 2/26 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.regenxbio.com
PDF vision health long term and overcoming the clinical challenges of managing wet AMD due to the treatment burden of chronic anti-VEGF injections Patients who received th [Read more]